Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

(17:37)

Patisiran for Transthyretin Cardiac Amyloidosis | NEJM

(2:5)

HFA 23: APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis

(3:12)

Onpattro (Patisiran) for Treatment of Polyneuropathy Caused by Hereditary ATTR Amyloidosis

(2:11)

Update on Patisiran to Treat Hereditary ATTR

(1:57)

Alnylam's Pending Approval of Patisiran

(1:7)

Treating hATTR Amyloidosis: Historical Overview

(6:17)

Dr.Gobind Rai Garg discusses the topic - Patisiran

(2:29)

Alnylam's New RNAi Therapy

(1:1econd)

Patisiran for Pat!

(9:)

What is RNAi and Who is Investing in the Treatment?

(2:44)

Patient living with hereditary ATTR Amyloidosis

(10:31)

New way to treat rare nerve disease

(2:2)

Optimism for amyloidosis therapy

(5:43)

New Treatment for hATTR Amyloidosis

(9:43)

RNAi Therapeutics - How this New Class of Medicines Works

(2:56)

Unboxing Patisiran/Onpattro for Hereditary Amyloidosis

(8:55)

The First FDA Approved RNAi Therapeutic ONPATTRO and Beyond

(30:26)

ATTR Peripheral Neuropathy Treatments

(16:48)

Medicine Grand Rounds: Novel therapies in cardiac amyloidosis 9/25/18

(46:47)